Coverage denials by payors are the main factor in a dramatic rise in failure to start hepatitis C drug treatment over the past three years, according to new data released March 8 by Trio Health, which has collected real-world evidence on 15,000 HCV patients since the launch of the direct-acting antiviral agents (DAAs) in 2014.
As of 2016, more than one-third of patients prescribed DAA treatment for hepatitis C did not receive therapy, according to the report.
Trio Health, a care-quality improvement company, estimated that in 2014, about 154,000 patients started DAA therapy for HCV, while another 12,281 were prescribed the treatment but did not initiate it, for a nonstart rate of 7%. In 2015, there were 256,000 starts and 55,492 nonstarts, for an 18% nonstart rate. By 2016, starts had dropped to 211,000 while nonstarts had climbed again, to 125,008—resulting in a nonstart rate of 37%.